200,000+ products from a single source!
sales@angenechem.com
6480-67-7 | 3-Quinolinecarboxamide
CAS No: 6480-67-7 Catalog No: AG00H68B MDL No:
Product Description
Catalog Number:
AG00H68B
Chemical Name:
3-Quinolinecarboxamide
CAS Number:
6480-67-7
Molecular Formula:
C10H8N2O
Molecular Weight:
172.1833
IUPAC Name:
quinoline-3-carboxamide
InChI:
InChI=1S/C10H8N2O/c11-10(13)8-5-7-3-1-2-4-9(7)12-6-8/h1-6H,(H2,11,13)
InChI Key:
BLTDCIWCFCUQCB-UHFFFAOYSA-N
SMILES:
NC(=O)c1cnc2c(c1)cccc2
Properties
Complexity:
205
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
172.064g/mol
Formal Charge:
0
Heavy Atom Count:
13
Hydrogen Bond Acceptor Count:
2
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
172.187g/mol
Monoisotopic Mass:
172.064g/mol
Rotatable Bond Count:
1
Topological Polar Surface Area:
56A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.1
Literature
| Title | Journal |
|---|---|
| Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). | The Prostate 20120601 |
| Quinoline-3-carboxamide derivatives as potential cholesteryl ester transfer protein inhibitors. | Molecules (Basel, Switzerland) 20120509 |
| Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. | Arthritis and rheumatism 20120501 |
| S100A9 interaction with TLR4 promotes tumor growth. | PloS one 20120101 |
| Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. | PloS one 20120101 |
| Emerging targeted therapies for castration-resistant prostate cancer. | Frontiers in endocrinology 20120101 |
| Specific effect of immunomodulatory quinoline-3-carboxamide ABR-215757 in GM-CSF stimulated bone marrow cell cultures: block of initiation of proliferation of Gr-1+ cells. | International immunopharmacology 20110801 |
| Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus. | Arthritis research & therapy 20110101 |
| The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. | Expert opinion on investigational drugs 20101001 |
| Selective depletion of splenic CD4 dendritic cells in mice treated with immunomodulatory quinoline-3-carboxamide ABR-215757. | International immunopharmacology 20100801 |
| Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration. | Bioorganic & medicinal chemistry letters 20100115 |
| Emerging therapies for treatment of multiple sclerosis. | Journal of inflammation research 20100101 |
| Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. | British journal of cancer 20091020 |
| Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. | PLoS biology 20090401 |
| Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. | Journal of medicinal chemistry 20090226 |
| The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. | The Prostate 20070515 |
| In search of effective anti-HHV-6 agents. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20061201 |
| Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. | Journal of medicinal chemistry 20061116 |
| Synthesis and reactivity of laquinimod, a quinoline-3-carboxamide: intramolecular transfer of the enol proton to a nitrogen atom as a plausible mechanism for ketene formation. | The Journal of organic chemistry 20060217 |
| Design, synthesis, and biological evaluation of novel 4-hydro-quinoline-3-carboxamide derivatives as an immunomodulator. | Bioorganic & medicinal chemistry letters 20050615 |
| Effect of Linomide on adhesion molecules, TNF-alpha, nitrogen oxide, and cell adhesion. | International immunopharmacology 20050201 |
| Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. | Journal of medicinal chemistry 20040408 |
| Semliki Forest virus infection is enhanced in Th1-prone SJL mice but not in Th2-prone BALB/c mice during Linomide-induced immunomodulation. | Journal of neuroimmunology 20021101 |
| Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system. | International immunopharmacology 20010601 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.